§
Luxuse
Patent Intelligence
Sign In
Patent US2052603A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5099003A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii

Assignee: Biotest Pharma GmbH
•
Filing: 1988-10-12
•
Granted: 1992-03-24
•
Expires: 2008-10-12
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method of preparing a sterile and stable plasma-protein solution containing fibrinogen and Factor XIII from human blood plasma which has been stabilized with citrate, comprising treating the plasma with beta -propiolactone and irradiating it with ultraviolet light, removing the Factors II, VII, IX and X by adsorption onto anion exchangers that adsorb proteins, precipitating the companion proteins out by adding ethanol until the solution has a final concentration of about 9% by volume at -3 DEG C., centrifuging the precipitate off, dissolving the precipitate in a citrate buffer at a pH of about 6.35 and a temperature of about 37 DEG C., adjusting the protein level of the solution to about 13.3 g/l with sodium citrate solution, adding ethanol, a glycine citrate buffer, and a solution of sodium citrate to precipitate out the companion proteins, adding ethanol to the remaining solution until the solution has a final concentration of about 9% by volume at -3 DEG C., thereby precipitating fribrinogen and Factor XIII, dissolving the precipitate in a citrate buffer at a pH of about 6.35 and a temperature of about 37 DEG C., and filtering the solution.

Inventors

  • 👤 Ronald Kotitschke
  • 👤 Axel W. Stemberger
  • 👤 Wolfgang Stephan

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 17:36
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/10; C12N9/1025; C12N9/104; C12N9/1044; A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61L; A61L2/00; A61L2/02; A61L2/16; A61L2/18; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/75; A61K38/00; A61L2103/00; A61L2103/05

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 201 words
A method of preparing a sterile plasma-protein solution containing fibrinogen and Factor XIII from human blood plasma which has been stabilized with citrate, comprising a) treating the plasma with βpropiolactone and irradiating it with ultraviolet light, b) removing the Factors II, VII, IX and X by adsorption onto anion exchangers that adsorb proteins, c) precipitating fibrinogen, Factor XIII and other proteins by adding ethanol until the solution has a concentration of about 9% by volume at -3° C., d) centrifuging off the precipitate of step (c), e) dissolving such precipitate in a citrate buffer at a pH of about 6.335 and a temperature of 37° C., f) adjusting the protein level of the solution to 13.3 g/l with sodium citrate solution, g) adding ethanol, a glycine citrate buffer, and a solution of sodium citrate to precipitate out companion proteins other than fibrinogen and Factor XIII, h) adding ethanol to the remaining solution until the solution has a concentration of about 9% by volume at -3° C., thereby precipitating fibrinogen and Factor XIII, i) dissolving the precipitate from step (h) in a citrate buffer at a pH of about 6.35 and a temperature of about 37° C., and j) filtering the solution.
Claim 2
Independent Claim 201 words
A method of preparing a sterile plasma-protein solution containing fibrinogen and Factor XIII from human blood plasma which has been stabilized with citrate, comprising a) treating the plasma with βpropiolactone and irradiating it with ultraviolet light, b) removing the Factors II, VII, IX and X by adsorption onto anion exchangers that adsorb proteins, c) precipitating fibrinogen, Factor XIII and other proteins by adding ethanol until the solution has a concentration of about 9% by volume at -3° C., d) centrifuging off the precipitate of step (c), e) dissolving such precipitate in a citrate buffer at a pH of about 6.335 and a temperature of 37° C., f) adjusting the protein level of the solution to 13.3 g/l with sodium citrate solution, g) adding ethanol, a glycine citrate buffer, and a solution of sodium citrate to precipitate out companion proteins other than fibrinogen and Factor XIII, h) adding ethanol to the remaining solution until the solution has a concentration of about 9% by volume at -3° C., thereby precipitating fibrinogen and Factor XIII, i) dissolving the precipitate from step (h) in a citrate buffer at a pH of about 6.35 and a temperature of about 37° C., and j) filtering the solution.
Claim 3
Dependent Claim 40 words
The method according to claim 1, wherein in step (a) the treatment with βpropiolactone is carried out at a range of concentration of about 0.2 to 0.35% by volume of the starting plasma and at a pH of about 7.2.
Claim 4
Dependent Claim 37 words
The method according to claim 1, wherein in step (b) the protein-adsorbing anion exchangers are crosslinked dextrans or celluloses with diethylaminoethyl groups and are employed in proportions of about 0.5 to 3 g per kg of plasma.
Claim 5
Dependent Claim 40 words
The method according to claim 1, wherein in step (g) the companion proteins are precipitated from 1 kg of fibrinogen solution with about 260 ml of ethanol, 240 ml of glycine citrate buffer, and 1500 ml of sodium citrate solution.
Claim 6
Dependent Claim 27 words
The method according to claim 1, wherein in step (i) the fibrinogen is finally dissolved to a concentration in the range of about 40 to 80 g/l.

References Cited (Backward Citations)

US4170590A Cited
US4435318A Cited
US4650678A Cited
US4600574A Cited
US4597899A Cited
US4627879A Cited
US4816251A Cited
US4822872A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-03-24 1995-09-23 1996-03-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-03-24 1999-09-23 2000-03-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-03-24 2003-09-23 2004-03-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag